GSK has completed its acquisition of Affinivax, which develops next-generation pneumococcal vaccines. GSK paid an upfront payment of $2.1 billion, and will pay about $1.2 billion more after certain development milestones are reached.

GSK completed the spin-off of its consumer healthcare division into a separate public company, Haleon. GSK distributed to shareholders 80% of its stake in Haleon, which was 68%. The new company received a portfolio of drugs such as Sensodyne, Voltaren, Panadol and Centrum. Haleon stock will begin trading today on the LSE under the ticker symbol HLN. In addit...

GSK shareholders voted to spin off the consumer healthcare division into a separate company, Haleon. GSK owns 68% of Haleon, of which 80% will be distributed to GSK shareholders. The new company will own a portfolio of drugs such as Sensodyne, Voltaren, Panadol and Centrum. Haleon shares will begin trading on the LSE on July 18, 2022.

GSK completed the acquisition of Sierra Oncology, a company specializing in the production of drugs for the treatment of rare forms of cancer. The transaction amounted to $1.9 billion.